Brazil’s weight-loss market poised for major shift as generic GLP-1 drugs approach

01 June 2026 Consultancy.lat 3 min. read

A major structural shift is hitting the Brazilian pharmaceutical landscape following the recent expiration of the Ozempic patent in March this year. According to a new study by global consultancy L.E.K. Consulting, the country is transforming into a highly segmented, two-tier market: A mass-market generic tier and a high-end premium tier.

While the shift is expected to nearly quadruple the number of users from 2.8 million to roughly 11 million, experts note that the market will still remain out of reach for the vast majority of the population.

Brazil has long offered inexpensive generic alternatives to popular drugs at a low cost. These generic drugs are produced in Brazil and contain the same active ingredient, at the same dosage, and they work in the same way as more expensive (and often imported) name-brand drugs. This program has been aimed at helping Brazilians of all economic backgrounds afford the medications they need.

Brazilian generic GLP-1s coming soon

Historically, the steep cost of weight-loss injections restricted usage to just 2% of Brazil’s active population. With a single box of Ozempic retailing for nearly $200 and competitor Mounjaro reaching up to almost $600, affordability has been the primary barrier to entry.

The end of Novo Nordisk’s patent protection is set to shatter this barrier. L.E.K. Consulting projects that the price of generic GLP-1 drugs will plummet by approximately 70% in pharmacies. This massive price reduction will unlock access for an additional 8 million Brazilians.

“Rapid expansion of access is expected as lower prices enable pharmacy-led substitution, driving the transition from niche to mass adoption,” according to L.E.K. Consulting.

Domestic pharmaceutical giants are already positioning themselves to capture this newly created entry-level segment. Analysts predict that EMS, which already manufactures liraglutide options, is poised to move the fastest into the market for these kinds of medications. Other major local players, including Eurofarma, Hypera Pharma, and Aché, are also expected to secure significant market share.

The premium market

Despite the influx of cheaper generics, wealthier consumers and top medical prescribers are expected to stick with brand-name, next-generation therapies. This premium segment will be sustained by patients looking for better results, superior tolerability, and fewer gastrointestinal side effects.

The premium tier will likely be anchored by advanced injections including high-efficacy medications like Eli Lilly’s Mounjaro and retatrutide (currently in development); and oral alternatives, like the weight-loss tablets from Novo Nordisk, designed specifically for patients who prefer to avoid injections.

“Brazil can evolve into a structurally segmented market,” the study states. “Higher-income patients and key prescribers should continue to value branded and next-generation therapies. Innovation competes primarily within the premium segment, not directly with generics.”

A global test case

Because Brazil’s weight-loss market relies almost entirely on direct, out-of-pocket consumer spending rather than government or insurance subsidies, the country has become the ultimate testing ground for the pharmaceutical industry.

The global medical community and international markets are closely watching how Brazilian consumers react during the second half of 2026. The country’s economic response to affordable semaglutide will serve as a crucial stress test for the future of the market.

“Brazil can be considered an initial stress test for the global post-generic GLP-1 market, as price-driven access expansion will reveal the dynamics of global demand,” according to the study.